Glycogen synthase kinase 3 (GSK3 ... Figure 5: Several signalling pathways induce the inhibition of GSK3 by phosphorylating the same serine residue near the amino terminus. Figure 6: The mechanism ...

In a notable study, researchers designed and synthesized novel compounds that act as dual inhibitors targeting both glutaminyl cyclase and glycogen synthase kinase-3β (GSK-3β), another enzyme ...

Aro Biotherapeutics, a clinical-stage biotechnology company working to develop potent and tissue-targeted medicines, today announced the dosing of the first patient in its clinical trial of ABX1100, a ...

The Phase Ib trial is set to test a gene therapy designed to target a rare disorder that causes muscle and respiratory failure.

With limited treatment options available for patients with PDAC, the EMA Orphan Drug Designation and FDA Orphan Drug Designation granted to elraglusib for the same indication reflect elraglusib’s ...

Actuate Therapeutics has gained orphan medicinal product designation (OMPD) from the European Medicines Agency (EMA) for elraglusib to treat pancreatic ductal adenocarcinoma (PDAC). The glycogen ...

An oral APOL1 inhibitor, MZE829 is under evaluation ... an exclusive worldwide licence agreement with Sanofi for the glycogen synthase 1 (GYS1) programme and MZE001, an oral substrate reduction ...